• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.少即是多：重新评估强化化疗在现代老年急性髓系白血病患者中的作用
J Clin Oncol. 2021 Oct 1;39(28):3104-3108. doi: 10.1200/JCO.21.00960. Epub 2021 Aug 18.
2
Lomustine in older patients with acute myeloid leukaemia.洛莫司汀用于老年急性髓系白血病患者。
Lancet Oncol. 2018 Nov;19(11):e584. doi: 10.1016/S1470-2045(18)30740-X. Epub 2018 Oct 4.
3
Intensive induction in older patients with acute myeloid leukemia: an initial struggle with later rewards?老年急性髓系白血病患者的强化诱导治疗：初期艰难但后期有回报？
Haematologica. 2024 May 1;109(5):1331-1333. doi: 10.3324/haematol.2023.284780.
4
Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
J Clin Oncol. 2011 Feb 1;29(4):349-51. doi: 10.1200/JCO.2010.32.2693. Epub 2010 Dec 20.
5
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病成人患者早期死亡的预测
Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11.
6
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.对立观点：标准治疗药物与研究性药物作为高危急性髓系白血病的初始治疗
Oncology (Williston Park). 2017 Mar 15;31(3):190, 192.
7
Point: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.观点：标准治疗药物与研究性药物作为高危急性髓系白血病的初始治疗手段
Oncology (Williston Park). 2017 Mar 15;31(3):190-1.
8
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.mTOR抑制剂依维莫司联合低剂量阿糖胞苷用于老年急性髓系白血病的Ib期研究。
Leuk Lymphoma. 2018 Feb;59(2):493-496. doi: 10.1080/10428194.2017.1334122. Epub 2017 Jun 8.
9
Treatment of older patients with acute myeloid leukaemia.老年急性髓系白血病患者的治疗
Lancet. 2010 Dec 11;376(9757):1967-8. doi: 10.1016/S0140-6736(10)62104-6. Epub 2010 Dec 3.
10
Management of primary refractory acute myeloid leukemia in the era of targeted therapies.靶向治疗时代的原发性难治性急性髓系白血病的治疗。
Leuk Lymphoma. 2019 Mar;60(3):583-597. doi: 10.1080/10428194.2018.1504937. Epub 2018 Sep 20.

引用本文的文献

1
Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial.5-氮杂胞苷用于不适于强化治疗且诱导化疗后有反应的急性髓细胞白血病患者的维持治疗：一项II期临床试验
Cancers (Basel). 2025 Aug 18;17(16):2678. doi: 10.3390/cancers17162678.
2
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.在成人急性髓系白血病中，使用去甲基化药物和维奈托克后进行强化化疗。
Blood Neoplasia. 2024 Aug 28;1(4):100038. doi: 10.1016/j.bneo.2024.100038. eCollection 2024 Dec.
3
From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights.从化疗到靶向治疗：通过遗传学和非遗传学见解解析急性髓系白血病的耐药性
Int J Mol Sci. 2025 Apr 24;26(9):4005. doi: 10.3390/ijms26094005.
4
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.异基因造血干细胞移植后老年急性髓系白血病患者诱导治疗类型对结局的影响。
Blood Adv. 2023 Jul 25;7(14):3573-3581. doi: 10.1182/bloodadvances.2022009632.
5
Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.急性髓系白血病干细胞的耐药机制
Front Oncol. 2022 Jul 5;12:896426. doi: 10.3389/fonc.2022.896426. eCollection 2022.
6
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.基于双核苷的低强度疗法治疗的60岁以上急性髓系白血病患者中ALFA 1200评分的验证
Blood Adv. 2022 Oct 11;6(19):5546-5549. doi: 10.1182/bloodadvances.2021006689.
7
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.先前接受过低甲基化剂治疗的继发性 AML 患者的一线治疗方法对其结局的影响。
J Hematol Oncol. 2022 Jan 29;15(1):12. doi: 10.1186/s13045-022-01229-z.
8
Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?异基因移植是老年急性髓系白血病患者的首选治疗方法吗？
Haematologica. 2022 Jul 1;107(7):1496-1497. doi: 10.3324/haematol.2021.279820.

本文引用的文献

1
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Venetoclax 和地西他滨治疗急性髓系白血病后可测量残留病的预后价值。
Blood Adv. 2021 Apr 13;5(7):1876-1883. doi: 10.1182/bloodadvances.2020003717.
2
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.CPX-351的真实生活经验及其对高危急性髓系白血病患者结局的影响：一项法国多中心队列研究
Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159.
3
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
4
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病中突变 TP53 变异等位基因频率的预后和治疗影响。
Blood Adv. 2020 Nov 24;4(22):5681-5689. doi: 10.1182/bloodadvances.2020003120.
5
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.有可测量残留病与急性髓系白血病患者生存结局的关联：系统评价和荟萃分析。
JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600.
6
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
7
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
8
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.美国血液学会2020年老年初诊急性髓系白血病治疗指南。
Blood Adv. 2020 Aug 11;4(15):3528-3549. doi: 10.1182/bloodadvances.2020001920.
9
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.成人急性淋巴细胞白血病的治疗进展：最新治疗方法及未来方向。
J Hematol Oncol. 2020 Jun 5;13(1):70. doi: 10.1186/s13045-020-00905-2.
10
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.美国急性髓系白血病患者接受阿糖胞苷-蒽环类诱导化疗的治疗模式及临床结局
Blood Adv. 2020 Apr 28;4(8):1615-1623. doi: 10.1182/bloodadvances.2020001728.

When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.

作者信息

Short Nicholas J, Kantarjian Hagop

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

J Clin Oncol. 2021 Oct 1;39(28):3104-3108. doi: 10.1200/JCO.21.00960. Epub 2021 Aug 18.

DOI:10.1200/JCO.21.00960
PMID:34406793
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8478366/
Abstract
摘要